Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
==== Polyol process ==== The polyol process is a particularly useful method because it yields a high degree of control over both the size and geometry of the resulting nanoparticles. In general, the polyol synthesis begins with the heating of a polyol compound such as ethylene glycol, 1,5-pentanediol, or 1,2-propylene glycol7. An Ag+ species and a capping agent are added (although the polyol itself is also often the capping agent). The Ag+ species is then reduced by the polyol to colloidal nanoparticles. The polyol process is highly sensitive to reaction conditions such as temperature, chemical environment, and concentration of substrates. Therefore, by changing these variables, various sizes and geometries can be selected for such as quasi-spheres, pyramids, spheres, and wires. Further study has examined the mechanism for this process as well as resulting geometries under various reaction conditions in greater detail.
The resulting Treaty of Córdoba, which was signed on 24 August, kept all existing laws, including the 1812 Constitution, in force until a new constitution for Mexico could be written. O'Donojú became part of the provisional governing junta until his death on 8 October. Both the Spanish Cortes and Ferdinand VII rejected the Treaty of Córdoba, and the final break with the mother country came on 19 May 1822, when the Mexican Congress conferred the throne on Iturbide. Spain initiated attempts to reconquer Mexico and it did not recognize Mexico's independence until 1836. Central America gained its independence along with New Spain. On 15 September 1821, an Act of Independence was signed in Guatemala City which declared Central America (Guatemala, Honduras, El Salvador, Nicaragua, and Costa Rica) independent from Spain. The regional elites supported the terms of the Plan of Iguala and orchestrated the union of Central America with the Mexican Empire in January 1822. One years later, following Iturbide's downfall, the region, with the exception of Chiapas, peacefully seceded from Mexico on 1 July 1823, establishing the Federal Republic of Central America. The new state existed for seventeen years, centrifugal forces pulling the individual provinces apart by 1840.
=== Detection in serum and plasma === Magnesium status may be assessed by measuring serum and erythrocyte magnesium concentrations coupled with urinary and fecal magnesium content, but intravenous magnesium loading tests are more accurate and practical. A retention of 20% or more of the injected amount indicates deficiency. As of 2004, no biomarker has been established for magnesium. Magnesium concentrations in plasma or serum may be monitored for efficacy and safety in those receiving the drug therapeutically, to confirm the diagnosis in potential poisoning victims. The newborn children of mothers who received parenteral magnesium sulfate during labor may exhibit toxicity with normal serum magnesium levels.
== Function == The TAP transporter is found in the ER lumen associated with the peptide-loading complex (PLC). This complex of β2 microglobulin, calreticulin, ERp57, TAP, tapasin, and MHC class I acts to keep hold of MHC molecules until they have been fully loaded with peptides.
Epithelial tissue is composed of closely packed cells, bound to each other by cell adhesion molecules, with little intercellular space. Epithelial cells can be squamous (flat), cuboidal or columnar and rest on a basal lamina, the upper layer of the basement membrane, the lower layer is the reticular lamina lying next to the connective tissue in the extracellular matrix secreted by the epithelial cells. There are many different types of epithelium, modified to suit a particular function. In the respiratory tract there is a type of ciliated epithelial lining; in the small intestine there are microvilli on the epithelial lining and in the large intestine there are intestinal villi. Skin consists of an outer layer of keratinized stratified squamous epithelium that covers the exterior of the vertebrate body. Keratinocytes make up to 95% of the cells in the skin. The epithelial cells on the external surface of the body typically secrete an extracellular matrix in the form of a cuticle. In simple animals this may just be a coat of glycoproteins. In more advanced animals, many glands are formed of epithelial cells.
Sources: en.wikipedia.org
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy in tablet form, and molly in crystal form, is an entactogen with stimulant and minor psychedelic properties. MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly used by attendees of dance parties, raves, and electronic dance music festivals. Tablets sold as ecstasy may be mixed with other substances such as ephedrine, amphetamine, and methamphetamine. The lethal risk from one dose of MDMA is estimated to be from 1 death in 20,000 instances to 1 death in 50,000 instances. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours. Short-term adverse effects include bruxism, blurred vision, sweating, and tachycardia, and extended use can also lead to addiction, amnesia, memory disorders, paranoia, and insomnia. Deaths have been reported due to increased body temperature and dehydration. MDMA acts primarily by increasing the release of the neurotransmitters serotonin, dopamine, and norepinephrine in parts of the brain. It belongs to the substituted amphetamine classes of drugs. MDMA is structurally similar to mescaline (a psychedelic), methamphetamine (a stimulant), as well as endogenous monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine.
Born in Algeria, Sebagh obtained a medical degree from the University of Paris and then learned plastic surgery in Los Angeles. For around 15 years, he worked to rebuild cancer victims' faces and heal burns victims' scarring in Paris's Hôpital Foch. In 1997, he divorced his wife, a Parisian dentist. He has a son and a daughter. Sebagh has a line of skin care products called Dr. Sebagh Anti-Aging marketed by Californian-based direct sales company Guthy-Renker and promoted through TV infomercials.
The project was originally estimated to cost $21.6 million and was to be the largest expansion project in the main branch's history; it entailed building 84 miles (135 km) of stacks, which could hold 3.2 million books. Construction on the stacks started after the park was closed. The park was excavated and the Great Lawn was rebuilt above it. Once the underground facilities were completed, Bryant Park was completely rebuilt, with 2.5 to 6 feet (0.76 to 1.83 m) of earth between the park surface and the storage facility's ceiling.
== Function == Little gastrin I stimulates Parietal cell in the stomach to secrete Hydrochloric acid. It does this partly by binding directly to Cholecystokinin B receptor on parietal cells, and partly by triggering Enterochromaffin-like cell to release Histamine, which then acts on parietal cells. Beyond acid secretion, it also plays a role in gastric motility and then release of Pepsin and Intrinsic factor.
=== Purity determination (w/w NMR) === While NMR is primarily used for structural determination, it can also be used for purity determination, provided that the structure and molecular weight of the compound is known. This technique requires the use of an internal standard of known purity. Typically this standard will have a high molecular weight to facilitate accurate weighing, but relatively few protons so as to give a clear peak for later integration e.g. 1,2,4,5-tetrachloro-3-nitrobenzene. Accurately weighed portions of the standard and sample are combined and analysed by NMR. Suitable peaks from both compounds are selected and the purity of the sample is determined via the following equation.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.